Company Overview - Harmony Biosciences is a U.S.-based biopharmaceutical company focused on therapies for rare neurological diseases, with WAKIX being a notable product for narcolepsy [5] - The company reported a total revenue of $825.94 million and a net income of $185.68 million for the trailing twelve months (TTM) [4] - The company has 268 employees and experienced a 1-year price change of -5.92% as of January 31, 2026 [4] Recent Executive Transactions - Sandip Kapadia, the Chief Financial Officer, sold 3,746 shares on January 26, 2026, for approximately $139,171 [1][2] - Following this transaction, Kapadia's direct holdings decreased to 24,521 shares from over 127,000 shares in March 2023 [8] - The transaction value was based on a weighted average purchase price of $37.15, with a post-transaction value of $916,105 based on the market close of $37.36 [2] Financial Performance and Outlook - Harmony Biosciences expects to achieve over $1 billion in revenue from WAKIX by the end of 2026, supported by an exclusive license for the medication [9] - The company has other medications in advanced development stages, projected to sustain operations into 2040 [10] - A 10% revenue increase is anticipated for 2025, indicating strong financial results and a positive outlook for investors [10] Investor Implications - Despite the recent sale by Kapadia, Harmony Biosciences' financials remain strong, particularly highlighted by a robust Q3 2025 net income, the highest since Q3 2022 [7] - The recent sale size of 3,746 shares is significantly below Kapadia's median sale size of 13,494 shares, suggesting a potential for further material sales [8]

Core Insights - Harmony Biosciences has shown promising financial performance, but the CFO, Sandip Kapadia, sold all her direct equity ownership in January 2026, raising questions about insider sentiment [1][6]. Financial Overview - As of January 31, 2026, Harmony Biosciences' stock price was $35.52, with a market capitalization of $2.1 billion, revenue of $825.94 million, and net income of $185.68 million [4]. - The transaction involved the sale of 20,961 shares for approximately $752,800, executed at a weighted average price of $35.92 per share [2][9]. Company Profile - Harmony Biosciences is a U.S.-based biopharmaceutical company focused on therapies for rare neurological diseases, with WAKIX being a notable product for treating narcolepsy [5]. Future Outlook - The company anticipates over $1 billion in revenue from WAKIX by the end of 2026, supported by an exclusive license for the medication [7]. - Other medications in advanced development stages are projected to sustain revenue generation into 2040, with a 10% increase in 2025 [8]. Insider Trading Context - Kapadia's sale fully liquidated her direct holdings, which had previously been reduced from 72,948 shares to zero over the past year [9]. - The sale price was slightly below the market close of $36.41 on the transaction date and below the current share price of $36.62 as of January 31, 2026 [9].

Key Takeaways CNX, GPN, HRMY, and UHS meet strict value criteria, including low P/CF and solid financial health.Each company is projected to grow both sales and EPS in the current financial year.All four stocks carry a Value Score of A and show consistent positive earnings surprises.The U.S. stock market remained subdued yesterday. While the Dow Jones Industrial Average gained 0.11% (+55.96 points) to 49,071.56, the broader market faced downside pressure. The S&P 500 slipped 0.13% to 6,969.01, while the tec ...

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, with Harmony Biosciences Holdings, Inc. (HRMY) identified as a strong candidate due to its favorable growth metrics and Zacks Rank [2][10]. Group 1: Earnings Growth - Harmony Biosciences has a historical EPS growth rate of 13.1%, but projected EPS growth for this year is significantly higher at 26.7%, surpassing the industry average of 13% [4]. - Double-digit earnings growth is a key indicator for growth investors, suggesting strong future prospects and potential stock price increases [3]. Group 2: Cash Flow Growth - The company currently exhibits a year-over-year cash flow growth of 10%, which is notably higher than the industry average of -4.5% [5]. - Over the past 3-5 years, Harmony Biosciences has achieved an annualized cash flow growth rate of 25.7%, compared to the industry average of 4.1% [6]. Group 3: Earnings Estimate Revisions - Recent upward revisions in current-year earnings estimates for Harmony Biosciences indicate a positive trend, with the Zacks Consensus Estimate increasing by 7.5% over the past month [8]. - The correlation between earnings estimate revisions and stock price movements supports the potential for near-term price appreciation [7]. Group 4: Overall Assessment - Harmony Biosciences has achieved a Zacks Rank of 1 (Strong Buy) and a Growth Score of B, indicating its potential as an outperformer and a solid choice for growth investors [10].

Key Points Harmony's approved narcolepsy drug Wakix has been a huge financial success. Controversy and litigation surrounding Wakix have held back the stock. Longer-term worries about patent cliffs and Harmony's pipeline have also been bearish influences. 10 stocks we like better than Harmony Biosciences › Finding value stocks in today's market environment is challenging. To find them in the biotech stock arena is even more unusual. Harmony Biosciences (NASDAQ: HRMY) specializes in biotechnology ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or argenex SE (ARGX) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies w ...

Key Points The biotechnology area includes many stocks that command premium valuations because of their future prospects. So when a more attractively priced option appears, it's worth closer examination. This biotech stock has a compelling story behind it. 10 stocks we like better than Harmony Biosciences › It's tough to be a value investor. For much of the past 15 years, the market environment has featured growth stocks that appear to be very expensive by most conventional value metrics. Even th ...

Core Insights - The article emphasizes the importance of the price-to-book (P/B) ratio as a valuation tool for identifying undervalued stocks with high growth potential, alongside more commonly used ratios like price-to-earnings (P/E) and price-to-sales (P/S) [1][5]. Group 1: Understanding P/B Ratio - The P/B ratio is calculated by dividing market capitalization by the book value of equity, helping investors assess whether a stock is under- or overvalued [1][5]. - A P/B ratio of less than one indicates that a stock is trading below its book value, suggesting it may be undervalued and a good buy, while a ratio above one may indicate overvaluation [5][6]. - The P/B ratio is particularly relevant for industries with tangible assets, such as finance and manufacturing, but may be misleading for companies with high R&D expenses or negative earnings [8]. Group 2: Stock Recommendations - Five stocks with low P/B ratios and strong growth potential are highlighted: BioMarin Pharmaceutical (BMRN), General Motors (GM), Harmony Biosciences (HRMY), Adient plc (ADNT), and Gibraltar Industries (ROCK) [2][9]. - BioMarin Pharmaceutical has a projected 3-5 year EPS growth rate of 20.11% and holds a Zacks Rank of 2 with a Value Score of A [15]. - General Motors is projected to have a 3-5 year EPS growth rate of 10.65% and has a Zacks Rank of 1 with a Value Score of A [16]. - Harmony Biosciences has a projected 3-5 year EPS growth rate of 25.66% and a Zacks Rank of 2 with a Value Score of A [16]. - Adient has a projected 3-5 year EPS growth rate of 15.7% and a Zacks Rank of 2 with a Value Score of A [17]. - Gibraltar Industries has a projected 3-5 year EPS growth rate of 15.0% and a Zacks Rank of 2 with a Value Score of A [18].

Core Viewpoint - Harmony Biosciences is entering 2026 with significant momentum driven by three key factors: strong performance of WAKIX, a robust late-stage pipeline, and a strong financial profile [3][4]. Group 1: WAKIX Performance - WAKIX has shown five years of consecutive growth and profitability, with guidance for 2026 indicating over $1 billion in net revenue, positioning it to achieve blockbuster status this year [3]. Group 2: Late-Stage Pipeline - The company has five Phase III programs in the clinic targeting five distinct CNS indications, which are expected to provide multiple catalysts in the coming years [4]. Group 3: Financial Profile - Harmony Biosciences is characterized by a strong financial profile, indicating profitability and a solid foundation for future growth [4].

Harmony Biosciences FY Conference Summary Company Overview - **Company**: Harmony Biosciences (NasdaqGM:HRMY) - **Event**: 44th JPM Healthcare Conference - **Date**: January 13, 2026 Key Industry Insights - **Core Focus**: Central Nervous System (CNS) disorders, particularly narcolepsy and related conditions - **Product Highlight**: WAKIX, a treatment for narcolepsy, is on track to achieve blockbuster status in 2026 with projected net revenue exceeding $1 billion Core Points and Arguments 1. **Momentum and Growth**: Harmony enters 2026 with significant momentum driven by three key factors: WAKIX performance, a robust late-stage pipeline, and a strong financial profile [2][3] 2. **WAKIX Performance**: WAKIX has shown five years of consecutive growth and profitability, with 2025 net revenue reported at $868 million, exceeding guidance [9][41] 3. **Pipeline Development**: Five phase three programs are advancing towards distinct CNS indications, setting up multiple catalysts for growth in the coming years [2][24] 4. **Pitolisant Franchise Expansion**: The introduction of Pitolisant GR (gastro-resistant formulation) and Pitolisant HD (high-dose formulation) aims to address unmet patient needs and expand the franchise [4][13] 5. **Market Opportunity**: There are approximately 80,000 diagnosed narcolepsy patients in the US, with an additional 90,000 undiagnosed, indicating significant growth potential for WAKIX [10][42] 6. **Commercial Strategy**: Harmony has improved its commercial operations, achieving broad formulary access (80% of lives covered) and enhancing patient support systems [11][27] 7. **Regulatory Milestones**: Anticipated NDA submission for Pitolisant GR in Q2 2026, with a PDUFA date expected in Q1 2027 [30][37] 8. **Financial Health**: Harmony maintains a strong balance sheet with over $770 million in cash, allowing for continued investment in pipeline development and business growth [44][45] Additional Important Insights - **Patient-Centric Approach**: The company emphasizes the importance of addressing patient needs, particularly in narcolepsy and related disorders, through innovative product formulations [4][14] - **Unique Product Profiles**: The differentiated profiles of Pitolisant formulations are expected to enhance clinical utility and market competitiveness [6][39] - **Future Catalysts**: Anticipated data readouts from ongoing trials in 2027 and 2028 for various CNS indications, including Prader-Willi syndrome and epilepsy programs [21][20] - **Business Development Focus**: Harmony is actively seeking strategic opportunities to expand its portfolio in the CNS space, particularly in orphan and rare diseases [44][45] This summary encapsulates the key points discussed during the conference, highlighting Harmony Biosciences' strategic direction, product pipeline, and market opportunities within the CNS industry.